⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | Nippon India Large Cap Fund - Growth - Direct Plan | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | — | HDFC MF |
| Category | Equity - Large Cap Fund | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹96.04 (30 Oct 2026) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★★★ | ★★★★★ |
| Benchmark | BSE 100 - TRI | BSE Health Care - TRI |
| Fund Manager | Sailesh Raj Bhan | Nikhil Mathur |
| Inception | 01 Jan 2013 | 04 Oct 2023 |
| Returns | ||
| 1Y | -9.48% | 22.64% |
| 3Y | 10.97% | 30.41% |
| 5Y | 11.91% | — |
| Since Inception | 14.58% | 29.15% |
| Risk | ||
| 12.93 | 14.07 | |
| 0.98 | 0.59 | |
| 0.31 | 1.59 | |
| 3.13 | 21.67 | |
| 0.56 | 3.48 | |
| -12.09% | -9.23% | |
| Costs | ||
| Expense Ratio | 0.88% | 1.03% |
| Exit Load | 1% on or before 7D, Nil after 7D | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹100 | ₹100 |
| Min Lumpsum | ₹100 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
Nippon India …96%
HDFC MF96%
3.6%Only 3.6% of holdings by weight are common between Nippon India Large Cap Fund - Growth - Direct Plan and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Common holdingNippon India Large Cap Fund - Growth - Direct PlanHDFC MF
Sun Pharmaceutical Industries Ltd.2.18%8.28%
Divi's Laboratories Ltd.1.45%9.39%
Category context: Equity vs Equity. Open the full Screener →